Last updated: September 24, 2026
Emapalumab-lzsg, marketed as Gamifant by Swedish specialty-pharmaceutical company Swedish Orphan Biovitrum AB (Sobi), is the first FDA-approved interferon-gamma antagonist for primary hemophagocytic lymphohistiocytosis (HLH). Its commercial profile is defined by a small but high-value patient population, hospital-based intravenous administration, orphan-drug pricing, limited direct competition, and expansion potential into secondary HLH and macrophage activation syndrome (MAS). U.S. sales have grown from a low base, but the product remains dependent on specialist diagnosis, reimbursement, and clinical adoption in life-threatening inflammatory disorders.
What is emapalumab-lzsg and how does Gamifant work?
Emapalumab-lzsg is a fully human monoclonal antibody that binds and neutralizes interferon gamma, a cytokine implicated in macrophage activation and the inflammatory cascade associated with HLH.
The FDA approved Gamifant on November 22, 2018, for adult and pediatric patients with primary HLH who have refractory, recurrent, or progressive disease, or intolerance to conventional HLH therapy. The approval was based on a single-arm clinical study in previously treated patients, with overall response assessed using clinical and laboratory criteria [1].
What disease does emapalumab treat?
The approved indication is primary HLH, a rare and potentially fatal hyperinflammatory disorder caused by genetic defects affecting immune-cell cytotoxicity. Patients may develop prolonged fever, cytopenias, splenomegaly, liver dysfunction, coagulopathy, and multiorgan failure.
Gamifant is used as part of a treatment strategy that may include corticosteroids, etoposide, hematopoietic stem-cell transplantation, and management of organ complications. It is not a broad immunosuppressive therapy for routine inflammatory disease.
What is the dosing and delivery profile?
Gamifant is administered by intravenous infusion. The recommended starting dose is 1 mg/kg, followed by dosing every three days, with escalation to higher doses when clinically necessary. Treatment continues until hematopoietic stem-cell transplantation or until the patient no longer requires therapy under the labeled treatment framework [1].
The intravenous route supports hospital and specialty-center administration. It also creates an operational barrier to substitution because treatment requires clinical monitoring, infusion capacity, and management of infection risk.
What is the FDA regulatory status of emapalumab-lzsg?
Gamifant has FDA approval under the biologics license application pathway and received orphan-drug and priority-review treatment. The approval includes a boxed warning regarding increased risk of infections, including serious and fatal infections, and recommends screening for latent tuberculosis and vaccination review before treatment where clinically appropriate [1].
| Regulatory item |
Status |
| Active ingredient |
Emapalumab-lzsg |
| Brand |
Gamifant |
| Sponsor and marketer |
Sobi |
| FDA application |
BLA 761107 |
| Initial FDA approval |
November 22, 2018 |
| Approved disease |
Primary HLH |
| Route |
Intravenous infusion |
| Regulatory category |
Biologic, orphan drug |
| Principal safety concern |
Serious infections |
| Key monitoring |
Infection, infusion reactions, liver abnormalities, cytopenias, disease activity |
The product’s label does not establish a broad indication for secondary HLH, cytokine-release syndrome, systemic juvenile idiopathic arthritis, or MAS. Use in those conditions depends on clinical evidence, physician judgment, institutional protocols, and reimbursement policy.
When does emapalumab lose exclusivity?
The principal statutory biologic exclusivity period for a reference product approved under the Public Health Service Act is 12 years from the date of first licensure, subject to regulatory interpretation and any applicable pediatric extension. On that basis, Gamifant’s core U.S. biologic exclusivity period runs approximately through November 2030, absent an applicable six-month pediatric extension [2].
Biologic exclusivity does not prevent a competitor from developing or filing a biosimilar during the development period. It prevents FDA approval of the biosimilar until the applicable exclusivity period expires.
Does Gamifant have Orange Book protection?
Gamifant is a biologic, not a conventional small-molecule drug. Its primary FDA reference is the Purple Book rather than the Orange Book. The Orange Book’s patent-listing framework for small-molecule products generally does not provide the principal market-exclusivity analysis for emapalumab-lzsg [2,3].
The commercial protection for Gamifant therefore depends on several layers:
- Twelve-year biologic reference-product exclusivity.
- Orphan-drug exclusivity for the approved indication.
- Patent rights covering the antibody, formulations, production methods, and therapeutic use.
- Manufacturing know-how and cell-line control.
- Clinical adoption and specialist distribution.
The orphan-drug exclusivity period is seven years from approval for the designated indication. Gamifant’s initial orphan exclusivity therefore extended beyond the approval date into late 2025, subject to the scope of the designation and statutory conditions [4]. That exclusivity does not block all biologic competition. It limits approval of another product for the same orphan indication when the competing product is considered the same drug and is clinically superior requirements are not met.
What patents protect emapalumab-lzsg?
Publicly available regulatory records identify Gamifant as an antibody biologic, but the principal U.S. market barrier is not an Orange Book patent listing. Protection is expected to be distributed across composition-of-matter, antibody-sequence, formulation, manufacturing, and method-of-use rights.
What formulations are protected?
The commercial product is an intravenous formulation of emapalumab-lzsg. Relevant protection can include:
- Antibody sequence and binding-site claims.
- Stable liquid or lyophilized formulations.
- Concentration, buffer, surfactant, and storage claims.
- Container-closure and reconstitution processes.
- Cell-culture and purification methods.
- Use in primary HLH and related hyperinflammatory disorders.
Formulation and manufacturing patents may be commercially important even after basic antibody claims expire. Their practical strength depends on claim scope, validity, enforceability, and whether a biosimilar applicant can design around them.
What method-of-use patents affect market entry?
Potential method-of-use protection is most relevant to treatment of primary HLH, refractory HLH, recurrent HLH, and interferon-gamma-driven inflammatory syndromes. Use patents generally provide narrower protection than composition claims because a competitor may challenge the patent, avoid the claimed indication, or launch for an unpatented use while accepting litigation risk.
How strong is the patent estate?
The estate is commercially stronger than a typical small-molecule estate in some respects because biosimilar development requires extensive analytical, process, and clinical work. Its legal strength is harder to assess from approval records alone because patent validity depends on issued claims, prosecution history, terminal disclaimers, continuation practice, and litigation outcomes.
The most durable barriers are likely to be:
- Reference-product exclusivity through approximately 2030.
- Proprietary manufacturing processes and cell lines.
- Small patient numbers that limit the economic attractiveness of biosimilar development.
- Specialist treatment pathways.
- Clinical evidence in a high-mortality disease.
The principal weakness is market size. A limited patient population may not support multiple competing biologics unless emapalumab expands into larger secondary HLH or MAS markets.
How has Gamifant revenue developed?
Sobi’s public reporting shows a rapid increase in Gamifant sales from the early commercialization period. The product became a strategic growth asset after Sobi acquired Novimmune, the original developer, in 2020. Sobi obtained control of emapalumab and related development capabilities through that transaction [5].
| Fiscal year |
Commercial development |
| 2018 |
U.S. FDA approval and initial launch |
| 2019 |
Early market formation in specialist HLH centers |
| 2020 |
Sobi acquisition of Novimmune |
| 2021 |
Increasing adoption and broader treatment-center penetration |
| 2022 |
Continued growth in U.S. primary HLH demand |
| 2023 |
Higher sales supported by diagnosis, referral, and treatment expansion |
Sobi reports Gamifant within its hematology and immunology portfolio. Public annual reports describe continued year-over-year growth, although reported figures can be affected by currency translation, portfolio classification, and geographic reporting conventions [6-8].
What drives Gamifant revenue?
Revenue depends on five commercial variables:
- Number of diagnosed primary HLH patients.
- Speed of treatment initiation after diagnosis.
- Duration of therapy before stem-cell transplantation.
- Reimbursement approval for an expensive orphan biologic.
- Expansion into secondary HLH, MAS, and other interferon-gamma-mediated conditions.
Treatment duration can materially change revenue per patient. A patient treated briefly before transplantation generates a different commercial outcome from a patient requiring prolonged induction, dose escalation, or bridge therapy.
What limits revenue growth?
The market has structural constraints:
- Primary HLH is exceptionally rare.
- Diagnosis often occurs in tertiary centers after severe clinical deterioration.
- Treatment overlaps with transplant and critical-care pathways.
- Long-term safety monitoring is required.
- Off-label use may face payer restrictions.
- Competing treatments are inexpensive relative to biologic therapy, even when evidence is less specific.
Gamifant’s growth case therefore relies less on price increases and more on increased diagnosis, earlier treatment, wider center adoption, and new indications.
Which companies are challenging emapalumab-lzsg?
No directly interchangeable FDA-approved biosimilar of emapalumab-lzsg had established U.S. commercial status in the public regulatory record through the available reporting period. Potential competition comes from three groups.
What biologic competitors exist?
There is no approved biologic with the same interferon-gamma mechanism and primary-HLH label. Other immunomodulatory products may compete clinically in secondary HLH, MAS, or cytokine-driven syndromes, but they are not direct substitutes for the Gamifant label.
Potential adjacent products include anakinra, tocilizumab, ruxolitinib, and JAK-pathway therapies. Their use depends on disease subtype and institutional practice.
What conventional therapies compete with Gamifant?
Conventional HLH treatment may include dexamethasone, etoposide, cyclosporine, intrathecal therapy, and hematopoietic stem-cell transplantation. These options can be used before, with, or after emapalumab depending on clinical circumstances.
The competitive distinction is evidence and mechanism. Gamifant directly neutralizes interferon gamma, while older regimens suppress immune activity through broader cytotoxic or immunosuppressive effects.
What biosimilar risks exist for Gamifant?
Biosimilar risk is likely to be limited before the end of the 12-year reference-product exclusivity period. After that point, the main risk depends on whether a biosimilar developer can justify the cost of development in a small market.
| Risk factor |
Effect on biosimilar entry |
| Small primary-HLH population |
Reduces commercial incentive |
| High development cost |
Raises break-even threshold |
| Intravenous administration |
Increases operational complexity |
| Specialist prescribing |
Slows automatic substitution |
| Manufacturing complexity |
Raises technical barriers |
| Potential secondary-HLH expansion |
Increases market attractiveness |
| Long biologic exclusivity |
Delays approval timing |
A biosimilar could still create price pressure without automatic pharmacy substitution. Hospitals and specialty centers may negotiate discounts, while physicians may retain discretion because patients are critically ill and treatment experience is concentrated.
What patent litigation and Paragraph IV risks affect Gamifant?
Paragraph IV litigation is primarily associated with the Abbreviated New Drug Application pathway for small-molecule products. A biosimilar applicant would generally use the Biologics Price Competition and Innovation Act process rather than a traditional Paragraph IV ANDA challenge.
The relevant litigation sequence would likely involve:
- Patent disclosure and negotiation under the BPCIA process.
- Declaratory or infringement litigation over disclosed patents.
- Patent validity and noninfringement challenges.
- Potential launch before patent expiry subject to litigation risk.
- Contractual settlement or license arrangements.
No major public biosimilar litigation or settlement involving emapalumab-lzsg had established commercial significance in the available record through the referenced period.
How does Gamifant compare with competing HLH treatments?
| Attribute |
Gamifant |
Etoposide-based therapy |
Corticosteroids |
Anakinra or JAK-pathway therapy |
| Mechanism |
Interferon-gamma neutralization |
Cytotoxic immune suppression |
Broad anti-inflammatory effect |
Cytokine or JAK-pathway modulation |
| FDA primary-HLH label |
Yes |
No comparable current label |
No |
No comparable primary-HLH label |
| Administration |
Intravenous |
Intravenous or other protocol-based use |
Oral or intravenous |
Variable |
| Evidence position |
Disease-specific biologic program |
Established HLH protocols |
Standard supportive component |
More dependent on disease subtype |
| Price profile |
High orphan-biologic cost |
Lower drug acquisition cost |
Low drug acquisition cost |
Variable |
| Main commercial advantage |
Targeted mechanism and approved indication |
Familiarity and protocol history |
Broad availability |
Potential utility in secondary disease |
Gamifant’s strongest commercial position is in patients with confirmed or strongly suspected primary HLH who need a targeted therapy and may proceed to transplantation. Its position is less secure in secondary HLH, where treatment practices are heterogeneous and clinical evidence is evolving.
What is the long-term market outlook for emapalumab-lzsg?
The base-case outlook is continued growth through the late 2020s, supported by U.S. specialist adoption and the absence of a direct biosimilar. The product’s revenue trajectory could accelerate if Sobi secures broader regulatory support for secondary HLH, MAS, or other interferon-gamma-driven syndromes.
The downside case includes:
- Slow diagnosis of primary HLH.
- Payer restrictions.
- Improved use of lower-cost immunosuppressive regimens.
- Failure of clinical development outside primary HLH.
- A biosimilar or competing biologic entering soon after exclusivity expiry.
- Limited treatment duration because of rapid transplantation.
Sobi’s economic exposure is meaningful at the product level but remains smaller than the company’s largest hematology and immunology franchises. Gamifant is strategically important because its rare-disease positioning provides pricing power and a platform for expansion, but it is unlikely to become a mass-market biologic without a broader indication.
Key Takeaways
- Gamifant is the first FDA-approved interferon-gamma antagonist for primary HLH.
- Sobi acquired control of the product through its acquisition of Novimmune.
- U.S. biologic exclusivity is expected to extend approximately through November 2030, subject to applicable extensions.
- Gamifant is governed primarily by Purple Book biologic rules rather than Orange Book listing practices.
- Revenue has grown since the 2018 launch, driven by specialist adoption and increased recognition of primary HLH.
- The main commercial opportunity is expansion into secondary HLH, MAS, and related hyperinflammatory conditions.
- Direct biosimilar risk is limited by market size, manufacturing complexity, intravenous delivery, and specialist prescribing.
- Conventional HLH regimens remain important price and treatment competitors.
- The product’s patent and manufacturing estate may extend practical protection beyond statutory biologic exclusivity, but the commercial value depends on claim scope and enforceability.
FAQs About Emapalumab-Lzsg and Gamifant
Is emapalumab-lzsg a biosimilar?
No. Emapalumab-lzsg is the reference biologic marketed as Gamifant. A biosimilar would require a separate FDA application demonstrating biosimilarity to the reference product.
Is Gamifant approved for cytokine-release syndrome?
Gamifant is not broadly FDA-approved for cytokine-release syndrome. Use in that setting depends on clinical evidence, institutional practice, and payer coverage.
Can Gamifant be substituted automatically at the pharmacy?
No. Gamifant is an infused biologic administered in a clinical setting. Interchangeability and substitution rules differ from those for conventional oral generic drugs.
What is the most important expansion opportunity for emapalumab?
Secondary HLH and macrophage activation syndrome represent the most commercially important potential expansion areas because they involve larger patient populations than genetically defined primary HLH.
Who owns the commercial rights to emapalumab-lzsg?
Sobi owns and commercializes Gamifant after acquiring Novimmune, the company that developed emapalumab, in 2020.
References
- U.S. Food and Drug Administration. (2018). Gamifant (emapalumab-lzsg) prescribing information.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
- Swedish Orphan Biovitrum AB. (2020). Sobi acquires Novimmune.
- Swedish Orphan Biovitrum AB. (2021). Annual report 2021.
- Swedish Orphan Biovitrum AB. (2022). Annual report 2022.
- Swedish Orphan Biovitrum AB. (2023). Annual report 2023.
